RSV-prevention products tied to lower infant hospitalization rates in 2024-25

Less than two years after RSV vaccines and preventive treatments became available, infant hospitalizations are already plummeting. This is prevention working exactly as intended.

https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-prevention-products-tied-lower-infant-hospitalization-rates

#NIAM2025

Infant hospitalization rates for respiratory syncytial virus (RSV) were 28% to 43% lower in 2024-25, the first US respiratory-virus season with broad availability of a maternal RSV vaccine (Abrysvo) and the preventive monoclonal antibody nirsevimab (Beyfortus) for infants, estimates a study in Morb...

Print

25